Diagnostic Microbiology & Infectious Disease
Volume 45, Issue 1 , Pages 73-76 , January 2003

Determination of disk diffusion and MIC quality control parameters for AZD2563, a novel long-acting oxazolidinone

  • Tamara R. Anderegg

      Affiliations

    • The JONES Group/JMI Laboratories, North Liberty, Iowa, USA
    • ,
  • Ronald N. Jones

      Affiliations

    • The JONES Group/JMI Laboratories, North Liberty, Iowa, USA
    • Tufts University School of Medicine, Boston, Massachusetts, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-319-665-3370; fax: +1-319-665-3371.
    • ,
  • the Quality Control Study Group1

      Affiliations

    • The JONES Group/JMI Laboratories, North Liberty, Iowa, USA
    • D. Biedenbach and A. Fuhrmeister (JMI Laboratories), G. Stein (Michigan State University), R. Rennie (University of Alberta), G. Hall (The Cleveland Clinic Foundation), A. Wanger (University of Texas), D. Hardy (Strong Memorial Hospital), T. Haugen (VA Medical Center, Iowa City), and J. Kenyon (Iowa State University).

Received 7 July 2002 ,Accepted 23 August 2002.

References 

  1. Anderegg TR, Biedenbach DJ, Jones RN. In vitro evaluation of AZD2563, a new oxazolidinone, tested against β-haemolytic and viridans group streptococci. J Antimicrob Chemother. 2002;49:1019–1021
  2. Anderegg TR, Biedenbach DJ, Jones RN. In vitro evaluation of AZD2563, a novel oxazolidinone, against 603 recent staphylococcal isolates. Antimicrob Agents Chemother. 2002;46:2662–2664
  3. Arundel, P. A. (2001). The new oxazolidinone, AZD2563: Physiologically-based pharmacokinetic extrapolation to man. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Abst. F-1039, p. 226. American Society for Microbiology, Washington, DC
  4. Craig, W. A., & Andes, D. R. (2001). Pharmacodynamic characteristics of AZD2563, the new oxazolidinone, in a murine thigh-infection model. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Abst. F-1037, p. 226. American Society for Microbiology, Washington, DC
  5. Diekema DJ, Jones RN. Oxazolidinone antibiotics. Lancet. 2001;358:1975–1982
  6. Gravestock, M. B., Betts, M. J., Chawner, E., Dawson, L., McGregor, A., & Mills, S. D. (2001). In vivo studies of novel oxazolidinones with O- and N-linked C-5 heterocyclic side-chains, including AZD2563. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Abst. F-1023, p. 222. American Society for Microbiology, Washington, DC
  7. Jones RN, Biedenbach DJ, Anderegg TR. In vitro evaluation of AZD2563, a new oxazolidinone, tested against unusual Gram-positive species. Diagn Microbiol Infect Dis. 2002;42:119–122
  8. National Committee for Clinical Laboratory Standards. (2000a). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A5. Wayne, PA: NCCLS
  9. National Committee for Clinical Laboratory Standards. (2000b). Performance standards for antimicrobial disk susceptibility tests, seventh edition. Approved standard M2-A7. Wayne, PA: NCCLS
  10. National Committee for Clinical Laboratory Standards. (2001). Development of in vitro susceptibility testing criteria and quality control parameters, second edition. Approved standard M23-A2. Wayne, PA: NCCLS
  11. National Committee for Clinical Laboratory Standards. (2002). Performance standards for antimicrobial susceptibility testing. Approved standard M100-S12. Wayne, PA: NCCLS

PII: S0732-8893(02)00482-0

doi: 10.1016/S0732-8893(02)00482-0

Diagnostic Microbiology & Infectious Disease
Volume 45, Issue 1 , Pages 73-76 , January 2003

Article Tools

* Image Usage & Resolution